Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Gilead Sciences Inc

2 Dividend Stocks That Could Pay You for the Rest of Your Life

As the market remains volatile due to ongoing concerns about elevated inflation, prolonged rate hikes, and an impending recession, fundamentally strong dividend stocks Bristol-Myers Squibb (BMY) Gilead Sciences (GILD) might be ideal buys to ensure a stable income stream. Moreover, these stocks could be great long-term investments. Read more.

StockNews.com

1 Resilient Growth Stock to Buy Now and Hold Forever

Biopharmaceutical giant Gilead Sciences’ (GILD) shares have risen nearly 30% over the past year despite lingering macroeconomic challenges. Moreover, the company delivered solid growth last year and is expected to maintain its business momentum in 2023 and beyond, driven by its diversified medicines portfolio. Hence, investors could consider buying and…

StockNews.com

The 3 Best Biotech Stocks to Buy for Under $100

Despite macroeconomic uncertainties, the biotech industry is anticipated to thrive amid robust demand and lucrative government initiatives. Given the promising prospects of the industry, quality stocks Gilead Sciences (GILD), Incyte (INCY), and Taisho Pharmaceutical (TAIPY) might be wise additions to your portfolio. These stocks are currently trading under $100. Keep…

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

2 COVID-19 Stocks That are Still Darlings in 2023

The COVID-19 pandemic caused immense volatility in the stock market, further aggravated by high inflation and consecutive rate hikes by the Fed. Amid the uncertainties, healthcare stocks tend to provide some hedge. We think COVID-19 darlings Pfizer (PFE) and Gilead Sciences (GILD) are still worth buying. Continue reading.

StockNews.com

3 Biotech Stocks to Buy in 2023 That Could Help Set You up for Life

The biotech industry is well-positioned to witness significant growth on the backs of soaring demands and government spending. Moreover, given the sector’s defensive nature, quality biotech stocks Amgen (AMGN), Gilead Sciences (GILD), and United Therapeutics Corp. (UTHR) might be solid buys in 2023 that could help you set for life.…

StockNews.com

The 3 Hottest Biotech Stocks to Own in 2023 and 1 to Avoid

Biotech companies are on track to stay resilient amid a potential economic slowdown due to their inelastic demand and continued breakthroughs. Therefore, it could be wise to invest in fundamentally strong biotech stocks Gilead Sciences (GILD), United Therapeutics (UTHR), and Jazz Pharmaceuticals (JAZZ). On the other hand, Bionano Genomics (BNGO)…

StockNews.com

3 Genius Dividend Stocks to Buy Now and Hold Forever

While the cooling price pressures have boosted investors’ sentiments this year, inflation is still far from the Fed’s target. Moreover, with recession possibilities still not off the table, quality dividend-paying stocks Gilead Sciences (GILD), Honda Motor (HMC), and Sysco (SYY) might be ideal buys now. Also, these stocks could be…

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

3 High-Value Stocks to Buy and Hold for a Lifetime

Despite showing signs of cooling, inflation is still well above the Fed’s 2% target. Moreover, January’s strong jobs report may encourage the Fed to raise interest rates even further, keeping the stock market highly volatile in the near term. Amid an uncertain macro environment, it could be wise to buy…

StockNews.com

1 Dividend Stock You'll Be Thankful to Own in 2023

With the market relapsing into a fresh bout of the volatility after estimate-crushing employment numbers, high dividend-yielding and fundamentally sound stock Gilead Sciences (GILD) could help investors secure a steady income stream. Read on….

StockNews.com

3 Must-Have Dividend Stocks for 2023

January’s robust job report is raising concerns about how long the Fed will keep interest rates high. Market experts are now expecting a higher terminal interest rate. As uncertainty clouds over, quality stocks Gilead Sciences (GILD), Valero Energy (VLO), and ARC Document (ARC) that pay stable dividends might be ideal…

StockNews.com

2 Stocks to Help Jump-Start Your Passive Income in 2023

Despite an inflow of positive macro data, the Fed’s hawkish stance is expected to keep the markets under pressure for the near term. With price fluctuations being the new norm, dividend-paying stocks with solid fundamentals, BHP Group (BHP) and Gilead Sciences (GILD), could help jump-start a solid stream of passive…

StockNews.com

These 3 Dividend Stocks Are Worth Investing In

While the better-than-expected GDP growth in the last quarter and declining inflationary pressures are raising optimism, macro uncertainties remain. With interest rate hikes expected to continue, recession possibilities cannot be ruled out. Therefore, fundamentally sound dividend-paying stocks, AbbVie (ABBV), Gilead Sciences (GILD), and Sisecam Resources (SIRE), could be worth investing…

StockNews.com

1 Biotech Stock to Buy in January 2023 and 1 to Sell

Amid rising demand and government investments, the biotech industry is poised to witness significant growth in the foreseeable future. Given this backdrop, quality biotech stock Gilead Sciences (GILD) might be a wise addition to your portfolio this January. However, Stoke Therapeutics (STOK) could be best avoided, given its bleak fundamentals.…

StockNews.com

1 High-Yield Dividend Stock You Can Count on in 2023

With the Federal Reserve committed to bringing inflation down, a pause in interest rate hikes is not expected this year. This is expected to lead to an economic slowdown and keep the stock market volatile. Amid this backdrop, investors could add a high-yield stock, Gilead Sciences (GILD), to stabilize their…

StockNews.com

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

3 Top-Rated Stocks to Buy for the Long Haul

Amid economic turmoil and recessionary fears, market volatility is anticipated to continue. However, this could be an opportune time for investors to scoop up quality top-rated stocks Gilead Sciences (GILD), Biogen (BIIB), and AudioCodes (AUDC) for the long haul. Read on….

StockNews.com

Get the Most Bang for Your Buck With These 3 Stocks

With data starting to reveal signs of a slowdown in an economy burdened with inflation and reactive interest rate hikes, loading up on fundamentally strong stocks Gilead Sciences (GILD), Kronos Worldwide (KRO), and Bluegreen Vacations Holding (BVH) at discounted valuations could set investors up for outsized returns. Continue reading….

StockNews.com

2 Nasdaq Stocks to Buy Now and Hold All of 2023

Thanks to easing inflation and indications of lower interest rate hikes by the Federal Reserve, the Nasdaq composite could rebound after its freefall last year. Given this backdrop, fundamentally sound Nasdaq stocks Cisco Systems (CSCO) and Gilead Sciences (GILD) could be ideal buy-and-hold options in 2023. Keep reading….

StockNews.com

2 Biotech Stocks Under $100 to Buy Now

The biotech industry flourished amid the pandemic, and lucrative federal investments are expected to drive further growth in the sector. Moreover, amid evolving variants of Coronavirus, the biotech industry is expected to remain in the limelight. Given the sound prospects of the industry, quality biotech stocks Gilead Sciences (GILD) and…

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

These 3 Stocks Pay You to Own Them

Although inflation has been showing signs of easing, it continues to hover way above the Fed’s 2% target. Since the Fed is expected to continue raising interest rates until its target is reached, the stock market is expected to remain volatile. Amid this backdrop, investors could consider investing in quality…

StockNews.com

3 High-Yield Dividend Stocks to Buy in a Sea of Market Volatility

The latest jobs report indicated that the Fed’s aggressive rate hikes have begun to yield results, but they still have a long way to go. With the market likely to be choppy in the near term, investors could invest in high-yield dividend stocks Gilead Sciences (GILD), KT Corp. (KT), and…

StockNews.com

Want Passive Income in a Bear Market? Check out This Biotech Stock

With the minutes of the latest Fed meeting showing that interest rates will keep increasing this year, the economy is widely expected to enter a recession. Amid the expected downturn this year, it could be wise to buy biotech stock Gilead Sciences (GILD) due to its solid growth prospects and…

StockNews.com

2 Biotech Stocks to Buy Amid a Blazing Hot Run

A rapidly aging population and the rise in lifestyle diseases drive the biotech industry’s growth. Through their cutting-edge research, biotech companies are coming up with new solutions to develop treatments. Given the solid long-term prospects of the industry, it could be wise to buy fundamentally strong biotech stocks Amgen Inc.…

StockNews.com

Consider Buying These 2 Biotech Stocks Before 2023

The biotech industry is expected to thrive amid the increasing medical requirements and greater investments in research and development. Moreover, investor sentiment toward biotech stocks has dramatically improved in recent months as the recession possibilities are rising. As this sector is known to provide a hedge against market downturns, investors…

StockNews.com

2 COVID-19 Stocks That Are Still Strong Buys

Given that COVID-19 is here to stay for the foreseeable future, investors could still benefit from their investments in companies that saw record-breaking sales during the pandemic’s height because of the effectiveness of their products in fighting the virus. With the potential resurgence of COVID-19 in several countries, Pfizer (PFE)…

StockNews.com

Up More than 19% In 2022, Is Gilead Sciences Still a Buy?

Gilead Sciences (GILD) beat revenue and earnings estimates in the previous quarter and upgraded its guidance for fiscal 2022. Having risen more than 19% year-to-date, is GILD still a buy? Read on to learn our view.

1 2 3 4 5

People

Dipanjan BanchurSince

722 stories

Mangeet Kaur BounsMangeet

595 stories

Santanu RoyHaving

215 stories

Sristi Suman Jayaswal

90 stories

Mike Wilson

67 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.